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ABSTRACT: Inhibition of excessive Toll-like receptor 4 (TLR4)
signaling is a therapeutic approach pursued for many inﬂammatory
diseases. We report that Mannoside Glycolipid Conjugates (MGCs)
selectively blocked TLR4-mediated activation of human monocytes and
monocyte-derived dendritic cells (DCs) by lipopolysaccharide (LPS).
They potently suppressed pro-inﬂammatory cytokine secretion and
maturation of DCs exposed to LPS, leading to impaired T cell
stimulation. MGCs did not interfere with LPS and could act in a
delayed manner, hours after LPS stimulation. Their inhibitory action
required both the sugar heads and the lipid chain, although the nature of
the sugar and the structure of the lipid tail could be modiﬁed. They
blocked early signaling events at the cell membrane, enhanced
internalization of CD14 receptors, and prevented colocalization of CD14 and TLR4, thereby abolishing NF-κB nuclear
translocation. When the best lead conjugate was tested in a mouse model of LPS-induced acute lung inﬂammation, it displayed
an anti-inﬂammatory action by suppressing the recruitment of neutrophils. Thus, MGCs could serve as promising leads for the
development of selective TLR4 antagonistic agents for inﬂammatory diseases.
Toll-like receptors (TLRs) serve as the ﬁrst line of defenseagainst invading pathogens such as bacteria and viruses.
They are notably expressed by monocytes, macrophages, and
dendritic cells (DCs). They activate the host defense system by
rapidly triggering inﬂammation.1 But TLR signaling is a double-
edged sword: although it leads to eliminating the invading
organisms, a deregulated response results in tissue damage and
ultimately contributes to the pathogenesis of chronic
inﬂammatory diseases.
TLR4 plays a key role in the innate host response to bacterial
infection. TLR4 recognizes the lipopolysaccharide (LPS)
present in the outer membrane of Gram-negative bacteria.
Activation of the signaling cascade is achieved by the successive
interaction of LPS with the lipopolysaccharide binding protein
(LBP), the cluster diﬀerentiation antigen CD14, and the
myeloid diﬀerentiation protein (MD-2) that binds LPS and
presents it in a monomeric form to TLR4.2 Upon LPS
recognition, TLR4 undergoes dimerization and recruits down-
stream adaptor proteins through interactions with its intra-
cellular domain.3 This initiates the intracellular signaling
cascade that culminates in translocation of transcription factors
to the nucleus and the biosynthesis of pro-inﬂammatory
cytokines and interferons leading to cellular activation.4,5 An
overly potent or prolonged TLR4 response is involved in acute
(septic shock)6 and chronic diseases (atherosclerosis,7 auto-
immune colitis,8 systemic lupus erythematosus,9 diabetes,10
Alzheimer disease11). Thus, blockade of excessive TLR4
signaling is a therapeutic approach that is actively pursued.
Recent links also emerged between TLR4 and breast cancer
oncogenesis, highlighting the development of novel therapeu-
tics for the targeting of TLR4 in breast cancer therapy.12 Small
molecules and nanoparticles active in modulating the TLR4
signal by targeting directly the MD-2-TLR4 complex or by
interfering with the TLR4 signaling have been described.13−15
However, the development of TLR antagonists as therapeutic
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agents has been slow, and so far none are approved for clinical
use.
We have previously described the properties of mannoside
glycolipid conjugates (MGCs) as antiviral agents.16,17 These
water-soluble compounds are formed by three building blocks:
a trimannose head, a hydrophilic linker, and a 24-carbon lipid
chain. MGCs eﬃciently target the mannose-binding lectins
Macrophage Mannose Receptor/CD206 and DC-SIGN/
CD209, thanks to the cooperation between the mannose
head and the lipid chain. They display biological activities as
single molecules and as self-assembled micelles, and inhibit
trans-infection of human immunodeﬁciency virus type 1 (HIV-
1) mediated by human DCs. Because intracellular signaling
from C-type lectins exerts inhibitory eﬀects on the TLR4
pathway,18−20 we hypothesized that MGCs could interfere with
TLR4-mediated cell activation.
In this report, we have investigated whether mannoside
glycolipid conjugates display anti-inﬂammatory responses on
TLR4-mediated signaling. We examined their eﬀects on LPS-
induced inﬂammatory reactions in human monocytes and DCs.
To decipher their mechanism of action, we studied the
importance of the sugar and the lipid moieties and tested
their eﬀect on the expression and location of cell membrane
proteins involved in TLR4 responses. Finally, we veriﬁed their
anti-inﬂammatory eﬀect in vivo in an acute model of LPS-
mediated pulmonary inﬂammation. Our data highlight the
potent anti-inﬂammatory action of MGCs both in cells and in
vivo.
■ RESULTS AND DISCUSSION
Conjugates 2 and 2U Are Not Pro-inﬂammatory. We
have reported previously the synthesis and physicochemical
properties of conjugates 2 and 2U (Figure 1). They exhibited
no cytotoxicity up to respectively 500 μM and 250 μM in MTT
viability assays on a human cell line.16,17 For human monocyte-
derived DCs, no cytotoxicity was measured up to concen-
trations of 150 μM in 7-AAD staining assays. In the presence of
LPS, some cytotoxicity was detected for compound 2 at 150
μM, but not for 2U (Supporting Information Figure 1Sa).
When conjugates alone were added to DCs, they did not aﬀect
the pro-inﬂammatory cytokine TNF-α level in the media
(Supporting Information Figure 2S), showing that conjugates 2
and 2U are not pro-inﬂammatory.
Conjugates 2 and 2U Act as TLR4 Inhibitors. We
examined the capacity of conjugates 2 and 2U to inhibit the
production of inﬂammatory cytokines as well as the maturation
of DCs stimulated with the TLR4 ligand, LPS. The media were
collected for measurement of cytokine concentrations by
ELISA, and cell surface maturation markers were labeled and
analyzed by ﬂow cytometry.
Stimulation of TLR4 activates the MyD88 (myeloid
diﬀerentiation primary-response protein 88)-dependent path-
way, which involves the early phase of nuclear factor-κB (NF-
κB) activation and leads to the production of pro-inﬂammatory
cytokines.1 When DCs were stimulated with LPS (1 μg mL−1),
simultaneous treatment with conjugates inhibited the release of
pro-inﬂammatory cytokines in a dose-dependent manner. The
highest concentration of conjugates (150 μM) completely
abrogated LPS-induced TNF-α and IL-6 release. Levels of IL-
12p70 were also potently reduced (Figure 2a). Depending on
the cytokine considered, the IC50 values of conjugates 2 and 2U
ranged between 12 and 28 μM (Supporting Information Table
1S).
Stimulation of TLR4 can also activate the MyD88-
independent pathway that relies on the adapter TRIF and
leads to the expression of interferon (IFN)-inducible genes and
the maturation of DCs.1 Conjugates at 50 μM were able to
totally inhibit IFN-β release triggered by LPS (Figure 2a).
Figure 1. Structure of conjugates. Trimannosides 2 and 2U are compared with conjugates containing lipid variations (1 contains no lipid chain; 3
and 4 have an omega-3 and omega-6 lipid chain; conjugates 5, 6, and 7 have a benzene-ending lipid chain; conjugate 8 contains a cholesterol motif)
or sugar variations (9 and 10, with galactose or sialic acid).
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In line with this, conjugates displayed a potent eﬀect on DC
maturation. The expression of cell surface markers CD86 and
HLA-DR was upregulated in the presence of LPS, as expected.
Co-treatment with conjugates potently inhibited this increased
expression in a dose-dependent fashion (Figures 2b and
Supporting Information 3Sa). The upregulation of other
maturation markers (CD80, CD83) was also impaired
(Supporting Information Figure 3Sa). Together, these results
demonstrate the potent anti-inﬂammatory activity of conjugates
2 and 2U on LPS-activated DCs. Thus, our results show that
conjugates can inhibit the two branches of downstream TLR4
signaling, MyD88- and TRIF-dependent pathways.
It was important to address the question whether the action
of conjugates on DCs leads to relevant physiological
consequences on cells of the immune system. DCs initiate
primary immune responses through their ability to conjugate
with naive T cells.21 Mixed leukocyte reactions were performed
by coculture of conjugate-primed DCs with naiv̈e T
lymphocytes. After 5 days, proliferation of T cells was analyzed
by CFSE dilution in ﬂow cytometry. Results showed that
conjugates 2 and 2U could inhibit T cell proliferation induced
by LPS-activated DCs (Supporting Information Figure 3Sb),
conﬁrming that the suppressive action of conjugates 2 and 2U
on activated DCs translates to T cell proliferation.
To investigate whether conjugates 2 and 2U were speciﬁcally
active on TLR4, we tested their eﬀect on other TLRs. When
DCs were stimulated with TLR agonists Pam3CSK4 (TLR1/2),
poly(I:C) (TLR3), and R-848 (TLR7/8), conjugates were
unable to signiﬁcantly aﬀect cell maturation markers and
cytokine release in a dose-dependent manner (Supporting
Information Figure 4S). Since IL-1β receptor signaling is also
linked to MyD88,22 conjugates were tested on the IL-1β
response. No signiﬁcant eﬀect was detected on IL-1β-induced
TNF-α production (Supporting Information Figure 4S). These
data indicate that the potent suppressive eﬀect of conjugates 2
and 2U is restricted to LPS stimulation of TLR4.
Conjugates Do Not Compete with LPS for Binding on
TLR4. To identify the mechanism involved in the anti-
inﬂammatory action of conjugates, we ﬁrst explored whether
they act by competing with LPS (Figure 3). DCs were
subjected to a 2-h stimulation with LPS alone, or with LPS and
conjugate 2U, followed by extensive washes (condition a, c).
To ensure complete elimination of LPS signaling, cells were
exposed to a TLR4 neutralizing antibody, in the absence of 2U
(condition b) or with the addition of 2U after 30 min
(condition d). After 24 h, as expected, LPS induced a dose-
dependent increase of CD86 expression and TNF-α production
(condition a), while the addition of LPS and 2U led to a
decreased CD86 expression and TNF-α production (condition
c). The TLR4 antibody led to decreased TNF-α production,
without aﬀecting CD86 expression (condition b). Conjugate
2U (condition d) induced a drastic reduction of CD86
expression and decrease of TNF-α production. These results
demonstrate that even after LPS removal and receptor
inactivation, conjugate 2U is still able to display its anti-
inﬂammatory eﬀect. This shows that compound 2U does not
act by competing with LPS on TLR4/MD2/CD14. Thus,
conjugates use a mode of action distinct from that of other anti-
inﬂammatory compounds such a PIM analogues that block LPS
Figure 2. Conjugates 2 and 2U displaying anti-inﬂammatory behavior
for LPS-treated DCs. Dose-dependent inhibition of (a) pro-
inﬂammatory cytokines TNF-α, IL-6, and IL-12p70 and of
interferon-β, released in the media after 24 h, (b) cell surface markers
HLA-DR and CD86 expression after 24 h. Nontreated cells (n.t.) are
indicated. MFI, mean ﬂuorescence intensity. Data correspond to n >
20 cell donors/independent assays.
Figure 3. Competetion between conjugate 2U and LPS binding.
Conjugate 2U does not compete with LPS binding. DCs were treated
with LPS or LPS+2U for 2 h, then washed before the indicated
treatments. (a) CD86 cell surface expression (MFI, mean ﬂuorescence
intensity) and (b) TNF-α production were analyzed after 24 h.
Representative data out of 2.
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binding to CD1423 or amphiphilic glycolipids that inhibit TLR4
activation by LPS by competitively occupying CD14.24
We investigated whether conjugates could aﬀect TLR4
signaling in a delayed manner following LPS stimulation. DCs
were treated with LPS, and compounds were added after a
delay of 2, 4, and 6 h (Figures 4 and Supporting Information
5S). Production of TNF-α was clearly reduced even with a 4
and 6 h delay, with respectively 2 and 2U. Similarly, CD86
expression was down-regulated after a 2 and 6 h delay, with
respectively 2 and 2U. These ﬁndings demonstrate the ability of
conjugates to inhibit the inﬂammatory response in a delayed
fashion, several hours after LPS stimulation. They further
support the notion that the conjugates do not act by competing
with LPS.
Conjugates Inhibit LPS-Induced NF-κB Activation.
Since the TLR4 signaling pathway culminates in the activation
of the NF-κB transcription factor, which regulates the induction
of cytokine genes, we examined the eﬀect of conjugates on NF-
κB activity. In resting cells, NF-κB/IκB complexes are present
in the cytoplasm. Activation leads to degradation of IκB, release
of free NF-κB that translocates into the nucleus to activate
genes with κB binding sites. We visualized the cellular location
of the NF-κB p65 subunit in the presence or absence of LPS
and conjugate 2 (Figure 5). As expected, p65 was found in the
cytoplasm of untreated DCs and in the nucleus of LPS-treated
cells. In the presence of 2, p65 was detected in the cytoplasm,
suggesting a block of its nuclear translocation. Similar results
were found with conjugate 2U, as shown on a ﬁeld of cells
visualized by confocal microscopy (Supporting Information
Figure 6S).
These data conﬁrm that the anti-inﬂammatory activity of
conjugates translates to an inability of NF-κB p65 to translocate
into the cell nucleus. They also suggest that conjugates act on
TLR4 signaling independently of the cross-talk with DC-SIGN
described with pathogens, which leads to increased accumu-
lation of nuclear p65.20
Conjugates Inhibit TLR4 Signaling Independently of
C-type Lectins. We tested whether the anti-inﬂammatory
behavior was speciﬁc for DCs or could occur in diﬀerent
immune cells. In human monocytes, conjugates also inhibited
LPS-induced production of pro-inﬂammatory cytokines TNF-
α, IL1-β, and IL-8 in a dose-dependent fashion (Supporting
Information Figure 7S). These results demonstrate that
conjugates can act on TLR4 signaling in distinct cells. These
ﬁndings questioned our cross-talk hypothesis, since monocytes
do not express C-type lectins DC-SIGN16 and MR.25 To
examine whether DC-SIGN is involved in the inhibitory eﬀect
of conjugates on TLR4, the eﬀect of the compounds was
compared in human monocytic THP-1-DC-SIGN cells and in
THP-1 cells (that do not express DC-SIGN and MR). In both
LPS-stimulated cell types, conjugates could inhibit IL-8
production (Supporting Information Figure 8Sa) and down-
regulate expression of the CD54 marker (Supporting
Information Figure 8Sb). These results indicate that the anti-
inﬂammatory action of conjugates can occur independently of
DC-SIGN expression.
To conﬁrm that DC-SIGN was not required in the anti-
inﬂammatory action of conjugates, we used the anti-DC-SIGN
antagonist antibody AZND1 that targets the carbohydrate
recognition domain.26 This antibody did abolish the activity of
mannodendrimers that inhibit LPS-treated DCs in a DC-SIGN-
dependent fashion.27 We found that preincubation of DCs with
this antibody had no eﬀect on TNF-α inhibition (Supporting
Information Figure 9S). These results conﬁrm that conjugates 2
and 2U have the capacity to inhibit TLR4 activation
independently of DC-SIGN. They also question the importance
of the role of the mannose heads of MGCs, previously shown
to interact in vitro with DC-SIGN.
Structure−Activity Relationship Studies: Importance
of the Mannose Heads and Lipid Chain. To elucidate the
role of the mannose heads of 2 and 2U during their suppressive
action, we used conjugates in which the mannose residues were
either lacking or replaced with sugars, such as galactose and
sialic acid, that do not interact with DC-SIGN or MR.
The NHPD conjugate constituted by a linker and a C24-lipid
chain, but lacking a sugar head,16 was totally inactive. Similarly,
the lipid docosahexaenoic acid (DHA) showed no eﬀect
(Figure 6a). These ﬁndings showed that a sugar head was
required for an eﬃcient immediate suppressive activity.
Figure 4. Delayed addition of conjugate 2U. The delayed addition
conserves inhibitory activity. DCs were treated with LPS, alone or with
2U added at the indicated times, or left untreated (n.t.). (a) TNF-α
production and (b) CD86 cell surface expression were analyzed after
24 h. Data correspond to n > 3 independent assays.
Figure 5. Cellular location of the NF-κB p65 subunit in the presence
or absence of LPS and conjugate 2. Conjugate 2 prevents NF-κB p65
nuclear translocation in LPS-treated DCs. (a) A representative
confocal microscopy image shows p65 in the cytoplasm of untreated
cells, in the nucleus of LPS-treated cells, and in the cytoplasm of cells
treated with both LPS and 2 (100 μM). (b) Histograms show the ratio
of cytoplasmic versus nuclear p65 analyzed in 170 cells. Bars
correspond to SEM.
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Conjugate TriGalC24 9 was previously described,
17 and
TriSialC24 10 was newly synthesized (Figure 1). They could
inhibit TNF-α production in LPS-treated DCs (Figure 6b, c)
and down-regulate maturation markers (Supporting Informa-
tion Figure 10Sa), although less eﬃciently than conjugates 2
and 2U (Figure 2c). Only TriGalC24 9 displayed some low
cytotoxicity at 150 μM in DCs (Supporting Information Figure
1Sb). Compound 2U bearing a diacetylenic motif was
photopolymerized under strong UV irradiation (8 h at 254
nm with 5 8W UV light tubes). This allowed us to compare the
activity of dynamic micelles 2U with rigid photopolymerized
cross-linked polymers 2UP.17 At low concentration, polymers
displayed a better inhibitory activity of TNF-α production
(Figure 6e), which highlights the role of the multivalent
mannose presentation in polymers.
Together, these results clariﬁed the role of the sugar moiety
in the suppressive activity, showing that the sugar head is
essential, with the optimal sugar being mannose compared with
galactose or sialic acid residues.
To better understand the structural requirements of the lipid
moiety and the importance of micelle formation, we
synthesized conjugates containing a variety of lipid chains
(Figure 1). To get a deeper insight into the physicochemical
properties, we measured the critical micelle concentration
(CMC) of all compounds (Supporting Information Table
SP1). The most active compounds 2 and 2U displayed low
CMC values by the pyrene inclusion method (around 10 μM).
Compounds 3 (TriMan-DHA) and 4 (TriMan-ARA) contain a
polyunsaturated fatty acids tail, respectively a docosahexaenoic
acid (DHA) omega-3, C21-lipid chain and an arachidonic acid
(ARA) omega-6, C19-lipid chain; they could not assemble into
micelles. In conjugates 5, 6, and 7, a benzene moiety was
covalently linked at the end of a C14-, C10-, and C6-saturated
lipid chain. Only compound 5 could form micelles, at a CMC
of 78 μM. We also synthesized conjugate 8 containing a
cholesterol motif, known to interact diﬀerently with cell
membranes, and able to form micelles at a CMC of 9.9 μM.
In primary cells, compounds 4 and 5 displayed no cytotoxicity
up to 150 μM. Compound 3 was slightly cytotoxic, and
compound 8 was cytotoxic even at 50 μM (Supporting
Information Figure 1Sc).
First, we found that conjugate 1, TriManC1, which lacks a
lipid chain, was unable to aﬀect LPS-induced cytokine release
(Figure 6d) and DC maturation (Supporting Information
Figure 10Sb), which demonstrated the importance of the lipid
chain. Compounds 3, 4, and 5, but not compounds 6 and 7
containing the shorter lipid chain, could eﬃciently inhibit TNF-
α production, with an activity similar to that of conjugate 2U
(Figure 6e). The apparent inhibitory activity of 8 was explained
by its cytotoxic eﬀect.
These results showed that conjugates can accommodate a
variety of lipid modiﬁcations (multiple double bonds, benzene)
and that a long lipid chain (at least C14) is crucial for activity.
They revealed that the formation of micelles is not required for
inhibition of cytokine production.
Down-regulation of activated maturation markers (Support-
ing Information Figure 10Sc) was achieved only by conjugate 5.
It inhibited both cytokine production and cell maturation, with
an activity similar to that of conjugates 2 and 2U. Photo-
polymerized micelles 2UP, having a caged lipidic core, were
unable to signiﬁcantly aﬀect marker expression, showing again
the importance of hydrophobic membrane interactions. This is
in full agreement with our hypothesis of a dual interaction
mode, since insertion into the cell membrane is blocked by
Figure 6. Structure−activity studies examining the inhibitory activity
of modiﬁed conjugates. TNF-α production of LPS-activated DCs was
analyzed after 24 h of treatment with compounds containing
modiﬁcations of the sugar head, (a) no sugar and (b) TriGalC24; (c)
TriSialC24; modiﬁcations of the lipid chain, (d) no lipid chain; and (e)
distinct lipid tails. Data correspond to n = 4 independent assays.
Figure 7. Eﬀects of conjugates on DC membranes. (a) Cell surface expression of CD14 analyzed by ﬂow cytometry, after 30 min of treatment with
indicated compounds. (b) A representative confocal microscopy image shows the cellular location of CD14 and TLR4 in permeabilized cells, after 30
min of treatment with indicated compounds. Size bars: 5 μm. (c) Pearson coeﬃcient of colocalization of CD14 and TLR4 in permeabilized DCs.
Each dot corresponds to a ﬁeld of 10−15 cells. Data correspond to n = 3 independent assays. Dots above the gray line (area noted as yes) have an
increased tendency for colocalization.
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cross-linking of the lipid chain resulting from the photo-
polymerization process.
The apparent eﬀect of 8 likely resulted from its cytotoxicity.
These ﬁndings revealed a correlation between micelle
formation and down-regulation of activated maturation
markers. They also showed that conjugates modulate cytokine
production and cell maturation by distinct TLR4-downstream
pathways.
Our data demonstrated that the formation of micelles is not
required for anti-inﬂammatory activity, such as inhibition of
TNF-α. However, micelle formation appears important for
modulation of the cell maturation markers. They stressed the
importance of a long-enough lipid tail in conjugates and
revealed that distinct lipid chains are functional, although they
can aﬀect diﬀerently TLR4-downstream signaling.
MGCs Act on Cell Membranes: They Internalize GPI-
Linked Proteins. Since the lipid tail of conjugates is essential
for their activity, it appeared crucial to investigate their
interaction with cell membranes. It is likely that the lipid
chain would insert into membranes and alter their composition.
The fatty acid composition of cell membranes inﬂuences their
ﬂuidity, which modulates membrane bound receptors. Mem-
branes contain microdomains, referred to as lipid rafts, which
incorporate speciﬁc proteins such as glycophosphatidylinositol
(GPI)-anchored proteins28,29
We examined the eﬀect of conjugates 2 and 2U on the cell
surface expression of two GPI-linked proteins, CD1a highly
expressed on DCs and CD14 involved in LPS cellular
activation. CD14 acts as an associated molecule of TLR4 and
plays a fundamental role in TLR4 signaling. DCs were treated
for 30 min with LPS or conjugates or both, followed by ﬂow
cytometry analyses. LPS alone did not modify the cell surface
expression levels of CD1a (Supporting Information Figure 11S)
and weakly (20%) downregulated CD14 (Figure 7a). In
contrast, levels of CD1a and CD14 were potently down-
regulated by conjugates 2 and 2U (respectively 35% and 60%).
These levels remained at their low values in the presence of
conjugates and LPS. Visualization of CD14 cell location
showed that the CD14 decrease at the cell surface correlated
with increased internalization (Figure 7b).
These results indicated that conjugates have a disruptive
action on lipid raft-located GPI-anchored proteins, CD1a and
CD14, and induce their rapid cell internalization. Thus, the
plasma membrane may be a principal target through which the
modulatory eﬀects of conjugates are mediated.
Our data agree with reports describing the eﬀects of
polyunsaturated fatty acids (PUFA) on key cell surface markers,
particularly CD14. Following DHA treatment, decreased levels
of membrane CD14 and enhanced cytosolic levels are detected
in microglial cells.30 Conjugated linoleic acid also suppresses
surface expression of CD14 during stimulation of macrophages.
In contrast, EPA- and DHA-treated macrophages show
enhancement of CD14 at the membrane along with decreased
levels in the cytosol.31 Of note, other raft-disrupting non-lipid
drugs, such as nystatin or methyl-β-cyclodextrin, inhibit LPS-
induced TNF-α secretion without alteration of the cell surface
expression of receptors involved in LPS activation but
redistribute proteins out of lipid rafts.28
MGCs Act on Cell Membranes: They Reorganize CD14
and TLR4 Location. In response to LPS, TLR4 is recruited to
lipid rafts and associates with the GPI-anchored CD14 protein.
This enhances the formation of a TLR4 dimer and association
of TLR4 with MD-2 and adaptor molecules TRIF and MyD88,
leading to the activation of downstream signaling pathways.
Thus, lipid raft integrity is essential for LPS-cellular activation,
proper TLR dimerization, and initiation of the signaling
cascade.32,33
Conjugates have a disruptive action on membrane integrity,
as shown above. We therefore examined whether 2U could
modify the respective localization of CD14 and TLR4, in the
absence or presence of LPS. As a control, we used the lipid
DHA that also disorganizes cell membranes. After 30 min of
treatment, DCs were labeled and images visualized by confocal
microscopy, followed by colocalization analysis (Figure 7b,c).
As expected, in control cells and upon DHA treatment, CD14
and TLR4 did not colocalize: CD14 was present at the cell
membrane, while most of TLR4 was cytoplasmic. LPS, as well
as conjugate 2U alone, induced CD14 internalization and some
colocalization with TLR4. Interestingly, the addition of both
LPS and 2U prevented colocalization and resulted in a situation
similar to that of control cells. Conjugate 2U behaved
diﬀerently from DHA, unable to prevent colocalization.
These ﬁndings showed that 2U alone disrupts the respective
localization of TLR4 and CD14 and promotes some
colocalization, but without inducing pro-inﬂammatory signal-
ing. Interestingly, in the presence of LPS, 2U could prevent
CD14 and TLR4 colocalization. These results suggest that the
inhibitory action of conjugates is mediated by their eﬀect on
cell membranes: they likely alter lipid raft composition and
interfere with the clustering of CD14 and TLR4 in rafts, which
leads to impaired receptor-complex formation and blocking of
signal transduction. This result may explain the extended eﬀect
of conjugates: they may block downstream signaling by
disrupting the clustering of CD14 and TLR4 in plasma and
endosomal membranes.
Similar eﬀects are described for PUFA that alter lipid raft
composition and interfere with their clustering, thus inhibiting
inﬂammation.34,35 Peptide 4F alters membrane ﬂuidity by
cholesterol depletion, which destroys clustering of CD14 and
TLR4 in rafts and leads to impaired receptor-complex
formation.36 DHA disrupts the organization of rafts but also
nonrafts and upon 24 h exposure inhibits the pro-inﬂammatory
eﬀects of LPS on DCs.37
Conjugate 2U Prevents Acute Lung Inﬂammation in
Mice. Since conjugates displayed a potent anti-inﬂammatory
activity in vitro, we tested whether the most active conjugate 2U
was active in a model of acute lung inﬂammation in response to
LPS in BALB/c mice. Conjugate 2U was administered
intraperitoneally at diﬀerent doses 1 h before LPS challenge.
Inﬁltration of immune cells, especially neutrophils, into the
lungs is an important component of the inﬂammatory response
in acute pulmonary injury.38,39 It was monitored after 24 h by
quantifying inﬂammatory cells, namely neutrophils, lympho-
cytes, and macrophages in the bronchoalveolar lavage ﬂuid
(Figure 8). Compared with the saline-treated mice, LPS
treatment induced a potent recruitment of neutrophils and
lymphocytes and did not alter the level of macrophages.
Interestingly, pretreatment with conjugate 2U before LPS
challenge reduced the recruitment of neutrophils and
lymphocytes in a dose-dependent manner, with a maximal
activity of about 40% at the dose of 100 mg/kg. These data
show that conjugate 2U has an anti-inﬂammatory action in this
mouse model, and actively prevents acute lung inﬂammation by
reducing neutrophil and lymphocyte recruitment.
Conclusions. These studies have established that MGCs
can display potent anti-inﬂammatory activities in human
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immune cells. They antagonize LPS-activated NF-κB signaling
and strongly suppress the release of pro-inﬂammatory cytokines
including TNF-α. Importantly, our lead conjugate 2U is active
in an acute mouse model of lung inﬂammation.
MGCs inhibit signaling through TLR4, without competing
with LPS for binding to TLR4. Our structure−activity analysis
indicates that the inhibitory activity of the conjugates relies on
their sugar head and mostly on their lipid chain. Important
roles of fatty acids in membrane order, lipid raft structure, and
membrane traﬃcking are beginning to be unraveled.40 In line
with this, our data showed that the eﬀect of MGCs on
inﬂammatory signaling occurs at the membrane level.
Conjugates induce a rapid cell internalization of lipid raft-
located GPI-anchored proteins such as CD14 and disrupt the
respective localization of TLR4 and CD14. Thus, the
mechanism accounting for the anti-inﬂammatory eﬀect of our
conjugates is most likely interference with early membrane
events involving CD14 and TLR4. Future investigations will be
necessary to decipher their precise molecular mechanism and
verify the hypothesis of disruption of TLR4 dimerization.
Finally, our data reveal the dual-functional roles of MGC,
able to exert both anti-inﬂammatory and antiviral17 activities.
This highlights the interest in MGCs that may provide new
therapeutic applications in distinct inﬂammation-driven dis-
eases.
■ METHODS
Cell Culture. All human primary cells and cell lines were cultured
at 37 °C and 5% CO2 in RPMI 1640 supplemented with gentamycin
and 10% (v/v) heat-inactivated fetal calf serum (complete medium).
Human monocytes were puriﬁed from buﬀy coats by successive Ficoll
and Percoll gradients. DCs were diﬀerentiated from monocytes by 5
days of culture with GM-CSF (50 ng mL−1; Schering-Plough) and IL-
4 (10 ng mL−1; ImmunoTools). Proper diﬀerentiation was
characterized by low CD14 and high CD1a and DC-SIGN expression
levels. THP-1 cells were acquired from ATCC. THP-1-DC-SIGN cells
are a kind gift from Dr. A. Sakuntabhai (Institut Pasteur, Paris,
France).
Flow Cytometry. The cells’ phenotype was analyzed using the
following antibodies from BD Bioscience: HLA-DR-FITC (Tü39 or
L243), MR/CD206-FITC (19.2), DC-SIGN/CD209-PerCP-Cy5.5
(DCN46), CD1a-APC (HI149), CD86-FITC (FUN-1), CD80-PE
(L307.4), CD83-APC (HB15e), CD54-PE (HA58), and CD14-PE
(MEM-15, ImmunoTools). Data were acquired on a FACSCalibur
(Becton-Dickinson) or Gallios (Beckman-Coulter) after exclusion of
dead cells by Sytox Red (Molecular Probes, Invitrogen) or 7-AAD
(BD-Pharmingen) DNA intercalating dyes. Data were analyzed using
the Cell Quest Pro software (BD Bioscience) or FlowJo (Treestar).
Cell Activation. Cells cultured in complete medium were
incubated in the presence of TLR ligands (InvivoGen): TLR2-TLR1
ligand Pam3CSK4 (1 μg mL
−1), TLR3 ligand double-stranded RNA
poly(I:C) (10 μg mL−1), TLR4 ligand Ultra pure E. coli K12
lipopolysaccharide (LPS: 10, 100, or 1000 ng mL−1), TLR7/8 ligand
R-848 (1 μg mL−1), or human IL-1β (300 ng mL−1; Aﬀymetrix,
eBioscience) at the indicated ﬁnal concentrations. MGCs were usually
added at the same time as the stimuli, or, where indicated, 2, 4, or 6 h
after LPS.
Enzyme-Linked ImmunoSorbent Assay (ELISA). After 24 h of
stimulation with TLR ligands, cell supernatants were collected and
stored at −20 °C. Levels of cytokines IL-1β, IL-6, IL-8, IL-12p70, and
TNF-α released in the media were measured by ELISA with the
corresponding BD OptEIA Set (BD-Pharmingen). Levels of IFN-β
were measured with the VeriKine human IFN-βELISA kit (PBL
Interferon Source).
Eﬀect on Cell Surface Proteins. DCs (105 cells) in complete
medium (200 μL) were plated in a 96-well plate. They were left
untreated or treated with conjugates (100 μM), LPS (1 μg mL−1) or
their combination for 30 min at 37 °C. They were washed, kept on ice,
labeled with anti-CD14-PE and anti-CD1a-APC, and analyzed by ﬂow
cytometry.
LPS Competition Assays. DCs were subjected to a 2-h
stimulation with LPS (10, 100, and 1000 ng mL−1) alone, or with
LPS and conjugate 2U (50 μM), followed by extensive washes. To
ensure complete elimination of LPS signaling, cells were exposed to a
neutralizing IgG monoclonal antibody to human TLR4 (InvivoGen,
mabg-htlr4; 5 μg mL−1) in the absence of 2U or with the addition of
2U after 30 min. After 24 h, cells were labeled with CD86, and
expression was measured by ﬂow cytometry. TNF-α secretion into the
media was quantiﬁed by ELISA.
Confocal Microscopy. Cells (105 per chamber) were cultured on
poly-L-lysine-coated, eight-chamber slides (Lab-Tek, Nunc) in
complete medium (300 μL). After treatments and labeling, DAPI
was used as nuclear counterstaining. Slides were mounted using
Fluoromount (Dako). Images were acquired on a Zeiss LSM 780
confocal microscope with GaAsP detector and Zen acquisition
software. Images were processed using the ImageJ software.
For NF-κB localization, DCs were treated or not with LPS, in the
presence or absence or conjugate 2 (100 μM). Cells were washed,
ﬁxed with PFA 4% for 5 min, permeabilized with PBS/Triton X-100
(0.1%) for 5 min, labeled with antihuman NF-κBp65-AF647 (Santa
Cruz Biotechnology), and ampliﬁed with antimouse IgG-AF488
antibody (Molecular Probes). The ratio of p65 ﬂuorescence intensity
in the cytoplasm versus in the nucleus was analyzed on 170 cells for
each condition. For colocalization analysis of CD14 and TLR4, DCs
were left untreated or treated with conjugates (100 μM) or DHA (20
μM) for 30 min. LPS (100 ng mL−1) was added for 30 min. Cells were
washed, ﬁxed, permeabilized, and labeled with anti-TLR4 polyclonal
goat antibody (R&D Systems AF1478, 5 μg mL−1) followed by AF488-
donkey antigoat (Molecular Probes, Invitrogen) and anti-CD14-APC
(ImmunoTools).
In Vivo Assays in BALB/c Mice. All animals received humane care
in compliance with the guidelines formulated by the French Ministry
of Agriculture and of Higher Education and Research, and all
procedures were reviewed by the Regional Ethical Committee for
Animal Experimentation of the University of Strasbourg. Conjugate
2U was solubilized in sterile saline (Braun) at 0.38, 1.25, 3.8, and 12.5
mg mL−1. Nine week-old male Balb/c mice received an intraperitoneal
(i.p.) administration of compound 2U (3, 10, 30, and 100 mg kg−1) 1
h before LPS intranasal administration (Sigma-Aldrich, L2880; 1 μg/
mouse). Six mice were used per condition. Control animals received
equivalent volumes of saline (8 mL/kg) by i.p. route.
Bronchoalveolar lavage (BAL) was performed 24 h after LPS
challenge as described.41 Mice were anaesthetized IP (Ketamine 300
mg/kg -Xylasine 20 mg/kg). After semiexcision of the trachea, a plastic
cannula was inserted, and airspace washed with PBS-EDTA (0.5 mL; 3
mM) with a 1 mL syringe. This procedure was performed 10 times.
Figure 8. Conjugate 2U is active in a mouse model of acute lung
inﬂammation. (a) Balb/c mice were treated with solvent or 2U
administered i.p., 1 h before LPS challenge. Results show the dose-
dependent inhibition of cell recruitment in BAL ﬂuid after 24 h. Bars
are SEM values (n = 6 per group). ###p ≤ 0.001 versus control group
and *p ≤ 0.05 versus LPS group.
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The remaining BAL ﬂuid was centrifuged (300g for 5 min, 4 °C). Cell
pellets were pooled, resuspended in PBS-EDTA (500 μL; 3 mM), and
used for total cell counts measured with a Celligo. Diﬀerential cell
counts were assessed by ﬂow cytometry (LSRII cytometer, BD
Bioscience). BAL cells were mixed with FcR-block (0.5 μL, 553142,
BD Bioscience) in a black microplate, incubated for 20 min at 20 °C.
Then, marker antibodies were added: CD11c-FITC (557400, BD
Biosciences), Gr-1-PE (12-5931-85, eBioscience), CD11b-APC-Cy7
(557657, BD Biosciences), and CD45-AlexaFluor700 (103128,
BioLegend), incubated for 30 min at 20 °C before 7-AAD (5 μL,
BD Biosciences) addition; ﬂow cytometry was performed immediately.
Live leukocytes were identiﬁed as CD45+/7-AAD− cells. They were
subdivided into lymphocytes (SSC-AlowCD11blow), neutrophils
(CD11b+CD11c−Gr1+), and macrophages (CD11b+Gr1−CD11c+).
Statistical Analysis. Statistical analysis was performed using paired
Student’s t test (for in vitro assays) or one-way ANOVA followed by
Tukey’s posthoc test (for in vivo assays). Data were considered
signiﬁcantly diﬀerent when p was less than 0.05.
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